Neo Comprehensive - Heme Cancers
Use
The Neo Comprehensive - Heme Cancers profile is a DNA + RNA panel that detects known mutations, CNVs and RNA fusions associated with most forms of hematologic malignant disorders, such as acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic myelogenous leukemia (CML), angioimmunoblastic T-cell lymphoma (AITL)/peripheral T-cell lymphoma (PTCL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), T/NK-large granular lymphocytic leukemia, among others. Testing using this panel can provide key diagnostic information, including critical molecular determinations affecting therapeutic approaches, can aid in risk stratification and predicting prognosis, and can also be used in clinical research.
Special Instructions
Test Customization: FLT3 by PCR (via FLT3 Mutation Analysis) is available for concurrent testing as a Client-Bill option. This result is reported separately to support prompt therapy selection in newly diagnosed AML cases. Please select Extract & Hold - TNA if specimen hold service is desired.
Limitations
Do not use zinc fixatives. Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies. Mercury fixatives (B5) should not be used.
New York Approved
Methodology
NGS
Biomarkers
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2-3 mL
Minimum Volume
Not provided
Container
EDTA tube
Storage Instructions
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible. NYS clients please provide date and time of collection.
Causes for Rejection
Mercury fixatives (B5). Highly acidic or prolonged decalcification processes.